New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2012
09:46 EDTMDCO, CYH, AUBN, WIRE, GRMN, CLH, TXRH, FIRE, CHSGappers report: Bullish gaps
This is a list of stocks making unusual moves on the open versus the prior day close. Gapping stocks often have excessive movements during the day and in the days thereafter. We use 5% for filter criteria and scanned for stocks that traded above $10 the prior day. GAPPING UP: WIRE 5.13%, CLH 5.26%, AUBN 5.57%, MDCO 8.11%, TXRH 9.26%, GRMN 9.71%, CYH 11.67%, CHS 13.35%, FIRE 17.09%.
News For AUBN;CHS;CLH;CYH;FIRE;GRMN;MDCO;TXRH;WIRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
17:49 EDTMDCOThe Medicines Co. up 7% after FDA panel backs approval of cangrelor
Subscribe for More Information
17:18 EDTMDCOThe Medicines Co. confirms FDA Advisory Committee backs approval of cangrelor
Subscribe for More Information
15:37 EDTMDCOFDA panel votes in favor of approval for cangrelor
Subscribe for More Information
08:40 EDTCYHHospital stocks rise in pre-market after HCA boosts 2015 guidance
Subscribe for More Information
07:57 EDTMDCOThe FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting
The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link
07:01 EDTMDCOThe Medicines Co. stock trading halted today
Subscribe for More Information
April 14, 2015
16:06 EDTCLHClean Harbors and Nuverra close acquisition of Thermo Fluids
Subscribe for More Information
07:03 EDTCLHClean Harbors acquires TFI from Nuverra Environmental for $85M
Clean Harbors (CLH) and Nuverra Environmental Solutions (NES) announced the close of Clean Harbors' planned acquisition of Thermo Fluids, or TFI, from Nuverra. Clean Harbors purchased Thermo Fluids for $85M in an all-cash transaction. Nuverra will apply 100% of the net proceeds received to reduce the outstanding balance under its asset-based revolving credit facility. Pursuant to the agreement, $4.25M of the proceeds was deposited into an indemnity escrow account to secure certain obligations of Nuverra under the purchase agreement. After giving effect to the indemnity escrow, the closing date working capital adjustment and the payment of transaction fees and expenses, the amount of net cash proceeds received by Nuverra on the closing date was approximately $74.6M.
April 13, 2015
11:13 EDTMDCOFDA panel briefing docs look positive for Medicines Co., says Leerink
Subscribe for More Information
10:15 EDTMDCOHigh option volume stocks
Subscribe for More Information
April 10, 2015
08:23 EDTGRMNGarmin may be appealing to value seekers, says Pacific Crest
Pacific Crest says its checks found no signs of a pause in demand for Garmin's (GRMN) products leading up to the release of Apple's (AAPL) Apple Watch. The firm suspects that Garmin may be less hurt by the Apple Watch than many believe, and it thinks downside risk from the launch of the Apple Watch has subsided. The firm believes that value seekers could see an opportunity in Garmin, but it keeps a Sector Perform rating on Garmin.
07:09 EDTMDCOThe Medicines Co. outlook still upbeat after preannouncement, says RBC Capital
After The Medicines Co preannounced lower than expected Q1 revenue, RBC Capital remains upbeat on the company's outlook, citing what it sees as the success of the company's gram negative franchise, its progress on earlier stage, cardiovascular candidates, and approval of and revenue support from up to four products in the near-term. The firm says the shares are "fundamentally inexpensive," while the company has a number of upcoming catalysts. It trimmed its price target on the shares to $37 from $38 but keeps an Outperform rating on the stock.
06:46 EDTMDCOThe Medicines Co. selloff a buying opportunity, says Leerink
Leerink views the selloff in shares of The Medicines Co. after the company preannounced weaker than expected Q1 revenue as a buying opportunity. The firm expects upcoming pipeline catalysts to create value in 2015. It thinks more visibility into four new products with significant revenue potential will move the stock higher. Leerink believes the preannouncement, driven by hospital customers buying fewer products due to the potential for a generic Angiomax to become available, should not come as a surprise. It keeps an Outperform rating on The Medicines Co.
April 9, 2015
16:32 EDTMDCOThe Medicines Co. down 15% after weaker than expected Q1 guidance
Subscribe for More Information
16:16 EDTMDCOThe Medicines Co. to resume trading at 4:30 pm ET
Subscribe for More Information
16:03 EDTMDCOThe Medicines Co. reports preliminary Q1 revenue $125M-$130M, consensus $184.17M
Subscribe for More Information
16:01 EDTMDCOThe Medicines Co. trading halted, pending news
Subscribe for More Information
09:18 EDTCHSBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
April 6, 2015
09:22 EDTGRMNGarmin trades lower after downgrade
Subscribe for More Information
06:20 EDTGRMNGarmin downgraded to Sell from Buy at Citigroup
Citigroup analyst Jeremy David downgraded Garmin two notches to Sell from Buy saying competitive pressures are likely to stall the growth of the company's GPS fitness watch business. He also thinks revenue trends in Garmin's Outdoor segment could disappoint as the year progresses. David expects Garmin to miss consensus earnings and revenue expectations in Q1 and views the Apple (AAPL) Watch launch as another potential negative catalyst for shares. He cut his price target for the stock to $42 from $68. Shares of the navigation and information device maker closed Thursday down 58c to $46.49 after Goldman Sachs downgraded the stock Neutral from Buy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use